Yet someone reported that PD-L1 antibodies could be an optional therapy for EGFR mutant NSCLC without targetable resistant mutations[35] due to the YAP (yes-associated protein) mediating, which needs further research. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.